
|Articles|October 1, 2003
Supplements and Featured Publications
- Biopharmaceutical Agents for Treating Rheumatoid Arthritis: Impact on Patients and Managed Care Heal
- Volume 9
- Issue 6 Suppl
Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate
Advertisement
Articles in this issue
about 22 years ago
Participating Facultyabout 22 years ago
Defining and Characterizing the Late-stage Biopharmaceutical PipelineNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
3
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
4
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
5















































